title: High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
abstract: OBJECTIVE
  To investigate the impact of high-dose hepatitis B immunoglobulin (HBIG) on hepatocellular carcinoma (HCC) and hepatitis B virus (HBV) recurrence and overall survival after living donor liver transplantation (LDLT).
  
  
  METHODS
  We investigated 168 patients who underwent LDLT due to HCC, and who were HBV-DNA/hepatitis B e antigen (HBeAg) -positive, from January 2008 to December 2013. After assessing whether the patients met the Milan criteria, they were assigned to the low-dose HBIG group and high-dose HBIG group. Using the propensity score 1:1 matching method, 38 and 18 pairs were defined as adhering to and not adhering to the Milan criteria. For each pair, HCC recurrence, HBV recurrence and overall survival were analyzed by the Kaplan-Meier method and the log rank test according to the HBIG dose.
  
  
  RESULTS
  Among those who met the Milan criteria, the 6-mo, 1-year, and 3-year HCC recurrence-free survival rates were 88.9%, 83.2%, and 83.2% in the low-dose HBIG group and 97.2%, 97.2%, and 97.2% in the high-dose HBIG group, respectively (P = 0.042). In contrast, among those who did not meet the Milan criteria, HCC recurrence did not differ according to the HBIG dose (P = 0.937). Moreover, HBV recurrence and overall survival did not differ according to the HBIG dose among those who met (P = 0.317 and 0.190, respectively) and did not meet (P = 0.350 and 0.987, respectively) the Milan criteria.
  
  
  CONCLUSIONS
  High-dose HBIG therapy can reduce HCC recurrence in HBV-DNA/HBeAg-positive patients after LDLT.
authors.affiliation: Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea.
authors.forename: Eung Chang
authors.initials: EC
authors.lastname: Lee
authors.affiliation: Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea.
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Kim
authors.affiliation: Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea.
authors.forename: Seung Duk
authors.initials: SD
authors.lastname: Lee
authors.affiliation: Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea.
authors.forename: Hyeongmin
authors.initials: H
authors.lastname: Park
authors.affiliation: Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea.
authors.forename: Soon-Ae
authors.initials: SA
authors.lastname: Lee
authors.affiliation: Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea.
authors.forename: Sang-Jae
authors.initials: SJ
authors.lastname: Park
mesh_terms: D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000401:mortality / Q000601:surgery* / Q000821:virology; D016009:Chi-Square Distribution; D004279:DNA, Viral / Q000097:blood* / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000401:mortality / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D057216:Propensity Score; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D014775:Virus Activation
chemical_list: D015415:Biomarkers; D004279:DNA, Viral; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin
keywords: Hepatitis B e antigen; Hepatitis B immune globulin; Hepatitis B virus-DNA; Hepatocellular carcinoma; Liver transplantation